CHST3
Basic information
Region (hg38): 10:71964395-72013558
Links
Phenotypes
GenCC
Source:
- spondyloepiphyseal dysplasia with congenital joint dislocations (Definitive), mode of inheritance: AR
- spondyloepiphyseal dysplasia with congenital joint dislocations (Strong), mode of inheritance: AR
- spondyloepiphyseal dysplasia with congenital joint dislocations (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Spondyloepiphyseal dysplasia with congenital joint dislocations | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Cardiovascular; Musculoskeletal | 112567; 9039660; 15368507; 15098240; 15215498; 17618475; 18513679; 18698629; 19320654; 20830804; 22539336 |
ClinVar
This is a list of variants' phenotypes submitted to
- Spondyloepiphyseal_dysplasia_with_congenital_joint_dislocations (306 variants)
- Inborn_genetic_diseases (46 variants)
- not_provided (30 variants)
- Larsen_syndrome (20 variants)
- Spondyloepiphyseal_dysplasia_congenita (19 variants)
- Skeletal_dysplasia (19 variants)
- not_specified (7 variants)
- Larsen-like_syndrome,_B3GAT3_type (3 variants)
- CHST3-related_disorder (3 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CHST3 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000004273.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 116 | 124 | ||||
missense | 19 | 144 | 182 | |||
nonsense | 10 | |||||
start loss | 1 | 1 | ||||
frameshift | 11 | 19 | ||||
splice donor/acceptor (+/-2bp) | 2 | |||||
Total | 29 | 27 | 155 | 124 | 3 |
Highest pathogenic variant AF is 0.0000592927
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CHST3 | protein_coding | protein_coding | ENST00000373115 | 2 | 49200 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00724 | 0.978 | 125657 | 0 | 21 | 125678 | 0.0000835 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.786 | 287 | 327 | 0.878 | 0.0000258 | 3044 |
Missense in Polyphen | 110 | 149.97 | 0.73347 | 1407 | ||
Synonymous | 0.219 | 146 | 149 | 0.977 | 0.0000128 | 966 |
Loss of Function | 2.13 | 6 | 14.9 | 0.403 | 6.50e-7 | 162 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000922 | 0.0000910 |
Ashkenazi Jewish | 0.000105 | 0.0000993 |
East Asian | 0.000112 | 0.000109 |
Finnish | 0.000238 | 0.000185 |
European (Non-Finnish) | 0.0000653 | 0.0000616 |
Middle Eastern | 0.000112 | 0.000109 |
South Asian | 0.000166 | 0.000163 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices. Can also sulfate Gal residues of keratan sulfate, another glycosaminoglycan, and the Gal residues in sialyl N- acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a role in the maintenance of naive T-lymphocytes in the spleen. {ECO:0000269|PubMed:9714738, ECO:0000269|PubMed:9883891}.;
- Pathway
- Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate - Homo sapiens (human);Metapathway biotransformation Phase I and II;Metabolism of carbohydrates;Chondroitin sulfate biosynthesis;Chondroitin sulfate/dermatan sulfate metabolism;Glycosaminoglycan metabolism;chondroitin sulfate biosynthesis (late stages);Proteoglycan biosynthesis;chondroitin sulfate biosynthesis;Metabolism
(Consensus)
Recessive Scores
- pRec
- 0.139
Intolerance Scores
- loftool
- 0.133
- rvis_EVS
- -0.34
- rvis_percentile_EVS
- 30.37
Haploinsufficiency Scores
- pHI
- 0.240
- hipred
- Y
- hipred_score
- 0.546
- ghis
- 0.524
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.319
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Chst3
- Phenotype
- endocrine/exocrine gland phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; hematopoietic system phenotype;
Gene ontology
- Biological process
- carbohydrate metabolic process;N-acetylglucosamine metabolic process;sulfur compound metabolic process;chondroitin sulfate biosynthetic process
- Cellular component
- Golgi membrane;trans-Golgi network;integral component of membrane
- Molecular function
- N-acetylglucosamine 6-O-sulfotransferase activity;sulfotransferase activity;chondroitin 6-sulfotransferase activity